SCHEMBL8536710

SCHEMBL8536710

Cc1[nH]c(=S)[nH]c(=O)c1C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 3/20 0.43
NSD2 O96028 1/20 0.40
CASP6 P55212 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.37
GAA P10253 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
PKM P14618 1/20 0.37
BRPF1 P55201 1/20 0.37
LMNA P02545 2/20 0.35
LPO P22079 1/20 0.34
PTGS1 P23219 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
THRB P10828 1/20 0.34
NPC1 O15118 1/20 0.33
FFAR3 O14843 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10238804 0.77 PDE3B (0.42) ALDH1A1NPSR1KDM4EPDE3BPDE3A
SCHEMBL3534627 0.72 L3MBTL1 (0.50) ALDH1A1NPSR1MAPTKDM4ENSD2
SCHEMBL13340874 0.72 GAA (0.50) ALDH1A1MAPTKDM4ENSD2L3MBTL1
SCHEMBL855321 0.70 L3MBTL1 (0.44) ALDH1A1NPSR1MAPTKDM4ENSD2
SCHEMBL11736849 0.68 KDM4E (0.46) ALDH1A1NPSR1MAPTKDM4ENSD2
SCHEMBL7037055 0.66
SCHEMBL7672761 0.65 ALDH1A1 (0.48) ALDH1A1NPSR1MAPTKDM4EL3MBTL1
SCHEMBL9872008 0.65 KDM4E (0.61) ALDH1A1NPSR1MAPTKDM4ENSD2
SCHEMBL18080347 0.64 PDE3B (0.39) PDE3BPDE3AGAA
SCHEMBL9640578 0.64 POLB (0.56) ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140073628-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE RICE KENNETH D (US) 2014-03-13 US disclosed
EP-2643315-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-10-02 EP disclosed
EP-2643317-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-10-02 EP disclosed
WO-2012071519-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed
WO-2012071501-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3533/4885NPSR1 1460/4885MAPT 1136/4885
US-20140073628-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE MTOR, RPTOR, RICTOR ALDH1A1 4794/4885NPSR1 1514/4885MAPT 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.